IFNA1 and myeloid sarcoma: In IFNβ treated MS patients, the baseline MxA mRNA (as a part of the IFN signature) has been recently reported to predict further clinical activity, i.e. a lower MxA mRNA level before treatment should correlate with a longer time until the next relapse [13].